Risk factor
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Operating in both domestic South Korean and international markets, JW Lifescience Corporation specializes in the development, manufacture, and distribution of intravenous infusion solutions. Its product range includes foundational intravenous fluids, which contain water, electrolytes, and glucose. The company also offers comprehensive nutrient infusion solutions, formulated to deliver vital components such as amino acids, lipids, proteins, vitamins, and minerals, in addition to various specialized infusion solutions. Founded in 1994, the enterprise, headquartered in Dangjin, South Korea, was previously known as JW Co. Ltd. before officially rebranding as JW Lifescience Corporation in April 2011.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced